Big Pharma wins more drug approvals, but fewer new sales

The good news: Big Pharma is doing better at winning regulatory approvals and advancing drugs to late-stage development. The bad: Newly approved meds aren't expected to deliver peak sales as high as those approved in prior years, a report from Deloitte and Thomson Reuters found. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.